Shots:The CHMP has recommended Xoanacyl (ferric citrate complex) for chronic kidney disease, with an EU decision expected by Jun 2025, while the UK's MAA will be filed via MHRA's IRP, with decision anticipated in the coming mos.MAA was filed via centralized European procedure in Mar 2024 & was supported by 3 pivotal trials…
Shots: Recently, AstraZeneca presented findings from the real-world IMPACT CKD study, which evaluated the multifaceted impact of CKD on patients, healthcare systems, and broader society, projecting future implications through 2032. The study emphasizes the importance of mitigating the economic burden on healthcare by implementing early, targeted screening, diagnosis, and treatment for CKD. In collaboration with…
Shots: The US FDA has approved the company’s Vafseo (vadadustat) tablets as a treatment of anemia associated with chronic kidney disease (CKD) in adults on dialysis for at least 3mos. The company, in collaboration with CSL Vifor, will commercialize Vafseo across the US The approval was based on the safety and efficacy results from INNO2VATE…
Shots:Anjay Rastogi, Professor, and Clinical Chief of Nephrology at UCLA, in an insightful conversation with PharmaShots, shares the highlights of AstraZeneca’s presentation at the American Society of NephrologyAt ASN 2023, AstraZeneca shares the analysis from the ZORA study, which is a global RWE program that describes the risk of progression to end-stage kidney…

